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Endometriosis is a common, hormone-dependent gynecologic disease. Undiagnosed in
large proportion of women, managing therapies depend on the impact of quality of life
and includes hormonal treatment and pelvic surgery. Less likely endometriosis can occur
in post-menopausal women. Malignant transformation of endometriosis is a rare but
well-described process, most of time occurring in the ovary, and justifies the practitioner
not to underestimate this pathology. We present a case of a 61 year old woman with
a symptomatic endometriotic pelvic mass, status post hysterectomy, with no history of
endometriosis diagnosed beforehand.
Keywords: endometriosis, malignant transformation, mullerian adenofibroma, post-menopausal woman,
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INTRODUCTION
Endometriosis is a benign, hormone-dependent and inflammatory disease. Described for the first
time in 1925, it is characterized by the presence of endometrial tissue outside of the uterine cavity,
occurring most commonly in fertile women (1, 2). The main symptoms are infertility and pain.
The exact prevalence of this disease remains unknown, but is thought to be around 6–10%, with
only 2–5% being diagnosed after menopause (3). Endometriosis can occur in post-menopausal
women with or without hormonal replacement therapy which indicates the complex mechanism
of perpetuation of this pathology. Hard to diagnose because of the absence of pathognomonic
symptoms or biomarkers, endometriosis in only confirmed by biopsy during laparoscopy.Magnetic
resonance imaging is a non-invasive option but with week sensitivity and no exclusion value (4).
Although endometriosis is a benign proliferative disease; it does share common characteristics
with neoplastic processes [inflammatory state, invasion of adjacent tissues, induction of
angiogenesis, and resistance to apoptosis (5)]. Malignant transformation of endometriosis is a
well-documented though rare phenomenon that occurs most commonly in the ovaries (6, 7).
However, it seems that endometriosis is not associated with an increased risk of cancer (8).
Sarcomas are a rare and heterogeneous group of malignant tumors of mesenchymal origin,
affecting principally soft tissues (80%) but also bones (20%) (9). The heterogeneity of sarcomas,
with regard to molecular genesis or histology pattern, makes its diagnosis very challenging.
This paper presents the case of a 61 year old woman, status post hysterectomy, presenting a
pelvic mass with vaginal bleeding and diagnosed with deep pelvic endometriosis.
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CASE STUDY
A post-menopausal 61 year-old 2G1P woman presented to
the Gynecology Obstetric Hospital in Freiburg, Switzerland, in
January 2018 for severe metrorrhagia without abdominal pain.
Medical history included high blood pressure and moderate
dyslipidemia. The patient was under hormone replacement
therapy (HRT). In her past medical history, the patient had a
cesarean and a total hysterectomy by laparotomy in 2000, without
ovariectomy, for menometrorrhagia (no morcellation needed).
The pathological report of the hysterectomy specimen showed
a focal hyperplasia of the endometrium without atypia and a
submucosal leimoyoma.
During her visit, the medical examination showed a normal
abdominal status and the vaginal palpation done by the junior
doctor seemed normal. Nevertheless, the speculum examination
revealed a budding mass of the vaginal dome. A vaginal
ultrasound showed a heterogeneous highly vascularized lesion
above the vaginal dome measuring 53 × 66mm. The ultrasound
showed a normal right ovary, the left ovary was not seen. There
was no free liquid in the peritoneal cavity. We partially stopped
the bleeding by dabbing with silver nitrate but as the bleeding was
not totally stopped, we performed an embolization of the right
and left vaginal arteries with coils (Figure 1).
Further anamnesis revealed that this mass had been known
since 2013 and discovered after a CT scan exam and ultrasound
performed because of vaginal bleeding. At that time, it
measured 45mm in its greatest dimension. The patient had
decided not to pursue further investigations as tumor markers
(Ca-125, Ca 19-9, Ca 15-3, alphaFP) were normal and for
personal reasons.
A first vaginal biopsy under local anesthesia produced
two small fragments of endometrial tissue with no atypia or
FIGURE 1 | The importance of the bleeding led to an embolization of the vaginal artery with coil fixing. (A) Before embolization. (B) After embolization.
malignancy (Figure 2). The biopsies did not contain any other
tissue and no vaginal epithelium was found. Given the small size
of the samples, new biopsies were suggested.
The abdominal CT scan and MRI found a hypodense
mass adjoining the vaginal dome possibly infiltrating the
posterior bladder wall and the rectum (Figure 3). The recto-
sigmoidoscopy was normal. A PET CT showed a high
vaginal uptake of 18F-FDG and no lymphadenopathy or
metastasis. The CT scan-guided biopsy produced small pieces
of endometrium with limited stromal changes (mild stroma
hyper-cellularity, with no significant atypia and very rare mitotic
figures), with no evidence of a malignant tumor (Figure 4).
The final pathological diagnosis was: endometrium without
malignant features.
However, multidisciplinary discussions between gynecologists
and pathologists, attempting to correlate a mass of unclear
location (“vaginal”) with histological findings, lead to the
potential hypothesis of a mullerian adenofibroma, a rare low
grade neoplasm of the gynecological tract. It associates benign
epithelial mullerian glands with a stromal component with few
atypia (close to the endometrial stroma) and would be difficult to
distinguish on small samples from its counterpart the low grade
mullerian adenosarcoma. The results of immunohistochemical
techniques, using antibodies against CD10, estrogen receptors,
and epithelial markers, though not specific, were consistent
with the mullerian adenofibroma hypothesis. Endometriosis was
discussed but not retained because of the notion of hysterectomy
in this patient.
Surgery was decided after multidisciplinary discussion. Before
the surgery, a double J probe was inserted in ureters. Initially,
a diagnostic laparoscopy was done, in conjunction with the
visceral surgeons, showing a diffuse adherential status resolved
by adhesiolysis. Bilateral adnexectomy by laparoscopy followed
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FIGURE 2 | Vaginal biopsies. The tissue transmitted for pathological analysis corresponds to endometrium, with numerous glands slightly irregular in size and shape
lined by cylindrical cells without nuclear atypia, and densely cellular stroma with signs of ancient bleeding, rare mitotic figures, and no cytologic atypia. (A) Hemalun
Eosin, magnification x4. (B) Hemalun Eosin, magnification x 10.
FIGURE 3 | Comparison of the 2013 and 2018 CT scanner showing an enlargement of the vaginal mass from 48 x 24mm to 76 x 47 mm.
FIGURE 4 | CT-scann guided core biopsies of a pelvic mass. This second series of biopsies again samples endometrium with a slightly denser stroma composed of
fusocellular cells with rare mitotic figures and no significant atypia. (A) Hemalun Eosin, magnification x4. (B) Hemalun Eosin, magnification x 10.
by a laparotomy conversion in order to extract the whole tumor.
The coagulation and removal of the mass pedicle resulted in
a bloc resection of the infiltrated recto-sigmoid with a small
part of the vagina. A discharge ileostomy was performed.
The operation lasted 8 h and the bleeding amounted to
about 850 cc.
There were no immediate postoperative complication.
Two weeks after the surgery, the patient developed a febrile
state with a painful renal percussion and inflammatory
syndrome with acute renal failure. After introducing
antibiotic for pyelonephritis, the patient underwent a CT
scan that showed a displaced right JJ probe that was removed
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the following day. The renal insufficiency was probably
multifactorial and due to a context of infection, ileostomy
liquid loss, toxicity of the antihypertensive drug, and acute
tubular necrosis.
The evolution was favorable. The vaginal bleeding stopped
after surgery. The ileostomy was closed 3 months later.
The pathological analysis of the 75mm large, highly
vascularized, rectosigmoid mass that had developed in the
sigmoid meso and the muscularis propria concluded to
endometriosis. Both ovaries harbored serous cystadenofibromas
(left ovary: 2.7 cm long axis, right ovary: 2.5 cm long axis). No
malignant neoplasm was found. No vaginal mucosa/wall was
identified within the surgical specimen.
After phone call with the patient February 2019, she does not
report any abdominal pain of vaginal bleeding. The last imagery
and clinical control in Mai 2018 was normal.
DISCUSSION
Because of the complex symptomatology and the invasive
manner of diagnosis, in the form of laparoscopy with visual
findings of the endometriosis lesions (4), the exact prevalence of
this pathology remains unknown. We suppose that an unknown
but probably large portion of the population is asymptomatic.
Pain is due to the inflammation-type reaction that gives rise to
adhesion and distortion of physiological pelvic anatomy, but the
degree of pain is not directly correlated to the severity of the
disease (10).
Estrogenic stimulation by the ovary during the reproductive
phase maintains endometriosis but, after menopause, several
mechanisms are supposed to lead to the hormonal continuance
which are hormone replacement therapy (HRT, without an
associated progestin), and other estrogen secretors such as
adipose tissue or the adrenal glands. Studies show that the
endometriotic tissue could secrete its own estrogen, confirmed
by the possible presence of aromatase expression in these ectopic
lesions (11, 12). Research suggests that the postmenopausal
state leads to a certain degree of immunosuppression that
could perpetuate endometriosis (13), but it is not known
whether it is a continuation of a past illness or a de novo
development (14).
Although the physiological ovarian estrogenic secretion
is over after menopause, this patient had several risk
factors for maintaining a hyper estrogenic state, favorable
to endometriosis, such as obesity and HRT (Estradiol,
4 years, stopped in 2018 before surgery). Retrospective
anamnesis, the patient did not report any pain or fertility
issues and the diagnosis of endometriosis was never
assumed beforehand.
The first choice of treatment of postmenopausal
endometriosis is a surgical procedure with optimal
cytoreduction, by carbon dioxide ablation, laser, or bipolar
diathermy (15), due to the risk of malignant degeneration
(16). Until now, there has been no consensus on the most
effective surgical technique to cure peritoneal disease and
prevent recurrence (17). Studies show that a patient treated
with ablation or excision of endometrioid lesion show a
reduction of symptoms such as dyspareunia and pelvic
pain (18).
The association of endometriosis with an increased risk of
malignancies has been described (19) but is debated in the
medical literature. Indeed, women with endometriosis were
more likely to develop ovarian cancer than healthy ones (20),
but the causality link is not clearly established. Most of the
time, malignant transformation of endometriosis is correlated
to endometrioids or clear cell carcinoma of the ovary (7). The
primary remaining question is the frequency of the malignant
transformation and, thus far, evidence is not strong enough.
In 2008, Kobayashi et al. estimated the risk of malignant
transformation for patient who suffer from pelvic endometriosis
of 1% (21).
Age is a risk factor for many malignancies, from which
we may hypothesize a higher malignant transformation
potential risk for postmenopausal women with
endometriosis (22).
For the moment, there are no recommendation for
“prophylactic surgery” in women with endometriosis because
of the malignant risk (8). Published in 2019, Kobayashi et al.
made a literature review about the advances in the imaging and
the non-invasive tests and biomarkers of early detection of the
malignant transformation of benign ovarian endometrioma
to endometriosis-associated ovarian cancer (23). Several
techniques are investigated such as electronic absorption
spectroscopy of cyst fluid hemoglobin or dosage of serum Tissue
Factor Pathway Inhibitor-2 (TFPI2) (elevated with malignant
transformation) (24).
Assuming a low-grade malignant tumor by viewing this
mass, and the bleeding symptomatology, we performed
surgery, but advanced endometriosis can be the cause of
error or incorrect intraoperative evaluation by infiltrating the
parametrium or lymphatic nodes or invasive procedures with
complications (25).
Histological findings of the CT scan biopsy suggest
a consistent with adenofibroma/sarcoma of low-grade
diagnosis. But we know that the diagnosis of sarcoma is
very difficult because of the histological and molecular
heterogeneity and the rareness of this disease (26).
Advances in management of sarcomas are made by
implementing molecular assays and could help orienting
the diagnostic (27).
Estrogenic dependency of endometriosis lesions explain
the therapeutic potential of aromatase inhibitors that block
the conversion from androgen to estrogen. This medication
showed value in patients who are not eligible for surgery
(28, 29) but this is not primarily recommended (30). Side
effects with menopausal patients such as osteoporosis and
fractures, hot flushes and vaginal dryness are to be considered
before introducing such a treatment. If surgery is not an
option, other painkiller medication is to be investigate,
such as Desogestrel (progestin without estrogen). A recent
study showed a reduction of pelvic endometriosis related
symptoms (pain, dysmenorrhea) compared to a placebo
group (31).
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CONCLUSION
It should be kept in mind that endometriosis is still an evocable
diagnosis even after menopause and even after hysterectomy.
The exact prevalence of endometriosis is still unknown because
of the pauci-symptomatic nature and the invasiveness of
the diagnostic procedure. Endometriotic lesions can mimic
malignant lesions by their infiltrative character and produce
a large panel of symptoms dependent on the site of the
damage. Endometriosis is associated with cancer types such as
endometrioid carcinoma of the ovary, but without proof of
a causal link. The main procedure for treatment is surgery
but should be balanced with the complication risks of a
surgical procedure.
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